Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: A phase III metastatic castration resistant prostate cancer trial
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: A phase III metastatic castration resistant prostate cancer trial
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF CANCER
Volume 136, Issue 8, Pages 1856-1862
Publisher
Wiley
Online
2014-09-13
DOI
10.1002/ijc.29212
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Circulating Tumor Cell Counts Are Prognostic of Overall Survival in SWOG S0421: A Phase III Trial of Docetaxel With or Without Atrasentan for Metastatic Castration-Resistant Prostate Cancer
- (2014) Amir Goldkorn et al. JOURNAL OF CLINICAL ONCOLOGY
- Serum Biomarkers of Bone Metabolism in Castration-Resistant Prostate Cancer Patients With Skeletal Metastases: Results From SWOG 0421
- (2014) Primo N. Lara et al. JNCI-Journal of the National Cancer Institute
- Cancer statistics, 2013
- (2013) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Phase III, Randomized, Placebo-Controlled Study of Docetaxel in Combination With Zibotentan in Patients With Metastatic Castration-Resistant Prostate Cancer
- (2013) Karim Fizazi et al. JOURNAL OF CLINICAL ONCOLOGY
- Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial
- (2013) David I Quinn et al. LANCET ONCOLOGY
- Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone With or Without Bevacizumab in Men With Metastatic Castration-Resistant Prostate Cancer: CALGB 90401
- (2012) William Kevin Kelly et al. JOURNAL OF CLINICAL ONCOLOGY
- Circulating Tumor Cells as Biomarkers in Prostate Cancer
- (2011) D. C. Danila et al. CLINICAL CANCER RESEARCH
- Circulating Tumor Cells as a Predictive Biomarker in Patients With Hormone-sensitive Prostate Cancer
- (2011) Oscar B. Goodman et al. Clinical Genitourinary Cancer
- TMPRSS2-ERG Status in Circulating Tumor Cells as a Predictive Biomarker of Sensitivity in Castration-Resistant Prostate Cancer Patients Treated With Abiraterone Acetate
- (2011) Daniel C. Danila et al. EUROPEAN UROLOGY
- A Cancer Detection Platform Which Measures Telomerase Activity from Live Circulating Tumor Cells Captured on a Microfilter
- (2010) T. Xu et al. CANCER RESEARCH
- Portable Filter-Based Microdevice for Detection and Characterization of Circulating Tumor Cells
- (2010) H. K. Lin et al. CLINICAL CANCER RESEARCH
- Detection of Androgen Receptor Mutations in Circulating Tumor Cells in Castration-Resistant Prostate Cancer
- (2010) Y. Jiang et al. CLINICAL CHEMISTRY
- Reprogramming Murine Telomerase Rapidly Inhibits the Growth of Mouse Cancer Cells In vitro and In vivo
- (2010) T. Xu et al. MOLECULAR CANCER THERAPEUTICS
- Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data
- (2009) Howard I Scher et al. LANCET ONCOLOGY
- Biomarkers for Prostate Cancer
- (2008) Danil V. Makarov et al. Annual Review of Medicine
- Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer
- (2008) J. S. de Bono et al. CLINICAL CANCER RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now